Tinnitus in Long COVID: Phenotype Classification and Combination Therapy
- 5 days ago
- 21 min read
Updated: 2 days ago
This paper is part of the CYNAERA Long COVID Library, a growing resource, impacting how infection associated chronic conditions are treated and understood.
By Cynthia Adinig
Key Findings and Summary
Tinnitus in Long COVID does not behave like a fixed auditory disorder. Instead, it demonstrates fluctuation in intensity, trigger sensitivity, and co-occurrence with systemic symptoms, suggesting that it reflects underlying instability across autonomic, immune, vascular, and neurocognitive domains rather than isolated cochlear or auditory pathway injury. Across the tinnitus literature, heterogeneity has long been recognized as a defining feature, with wide variation in symptom presentation, severity, and treatment response (Baguley et al., 2013; Cederroth et al., 2019; Kleinjung et al., 2024). In parallel, Long COVID is now widely characterized as a multi-system condition involving immune dysregulation, autonomic dysfunction, endothelial injury, neuroinflammation, and relapsing symptom trajectories (Nalbandian et al., 2021; Davis et al., 2023; National Academies of Sciences, Engineering, and Medicine, 2024).
Recent large-scale meta-analytic data further reinforce that Long COVID symptoms are both persistent and dynamic, affecting approximately 28–35% of individuals and showing no meaningful decline beyond six months, while symptom profiles shift across variants and time (Lugtu et al., 2026) . This combination of persistence and variability suggests that symptoms are not static sequelae, but evolving outputs of interacting biological systems. Within this context, tinnitus may be more accurately interpreted as a state-dependent neurovascular signal, emerging when autonomic instability, immune-mediated inflammation, vascular dysregulation, and central nervous system sensitization converge.
This paper advances three central arguments. First, tinnitus heterogeneity reflects underlying system-state differences rather than randomness. Second, Long COVID provides a uniquely informative model for tinnitus classification due to visible symptom clustering and trajectory patterns. Third, effective management is unlikely to rely on single interventions and instead requires phenotype-aligned combination strategies that stabilize upstream drivers of sensory amplification.
1. Introduction: Why Long COVID Changes the Tinnitus Question
Tinnitus is defined as the perception of sound in the absence of an external acoustic source and affects an estimated 10–15% of the population, with a smaller proportion experiencing clinically significant distress (Baguley et al., 2013; Bhatt et al., 2016). Despite its prevalence, tinnitus remains difficult to treat, in part because it represents a heterogeneous group of conditions rather than a single disease entity (Cederroth et al., 2019; Kleinjung et al., 2024).
Traditional models have focused on structural and perceptual mechanisms, including cochlear hair cell damage, auditory nerve dysfunction, and maladaptive central auditory processing (Shore et al., 2016). These frameworks are well supported in patients with hearing loss or identifiable otologic pathology. However, they do not fully explain tinnitus that fluctuates with stress, sleep, environmental exposure, or systemic illness. The emergence of tinnitus in Long COVID highlights this limitation. A systematic review conducted during the COVID-19 pandemic estimated a pooled prevalence of tinnitus following infection of approximately 8%, while emphasizing the lack of consistent patterns in onset, duration, or severity (Beukes et al., 2021). Additional reports of tinnitus following COVID-19 vaccination similarly describe heterogeneous presentations and suggest potential roles for immune activation, vascular dysfunction, and neuroinflammation (Yellamsetty et al., 2025).
At the same time, Long COVID has shifted the broader understanding of post-viral illness. It is now widely recognized as a multi-system condition involving persistent immune activation, autonomic instability, endothelial dysfunction, and neurological disruption (Nalbandian et al., 2021; Turner et al., 2023). Patients frequently experience relapsing or fluctuating symptoms influenced by exertion, stress, environmental exposure, hormonal shifts, and infection.
Large-scale analyses reinforce that these symptoms are not transient. A meta-analysis of over 150,000 patients found that post-COVID symptoms persist in a substantial proportion of individuals and show no meaningful reduction beyond six months, while symptom profiles shift across viral variants and follow-up periods (Lugtu et al., 2026) . Pre-Omicron variants were more strongly associated with respiratory and sensory symptoms such as dyspnea and anosmia, whereas later variants showed higher prevalence of neurocognitive symptoms, including brain fog and paresthesia.
These findings are critical for tinnitus interpretation. They indicate that symptom expression is not static, but instead evolves in response to changing system conditions. This dynamic behavior challenges the assumption that tinnitus in post-viral contexts reflects fixed structural injury.
A more coherent interpretation is that tinnitus represents a shared output of multiple interacting systems, whose expression depends on the stability of the underlying biological terrain. Long COVID, with its visible clustering of symptoms and triggers, provides a rare opportunity to study this relationship directly.
2. Tinnitus as a State-Dependent Neurovascular Signal
A state-dependent model of tinnitus emerges when autonomic, immune, vascular, and neural processes are considered together rather than in isolation. Autonomic dysfunction is a well-documented feature of Long COVID, with patients frequently exhibiting postural orthostatic tachycardia syndrome (POTS), orthostatic intolerance, and impaired vascular regulation (Barizien et al., 2021; Dani et al., 2021). These changes influence cerebral and cochlear perfusion, both of which are highly sensitive to fluctuations in blood flow. Vascular contributions to tinnitus have long been recognized, particularly in conditions involving altered microcirculation or endothelial dysfunction (Nomiya et al., 2013; Sismanis, 2003).
Simultaneously, persistent immune activation is increasingly recognized as a central feature of Long COVID. Studies have identified sustained cytokine elevation, altered T-cell populations, and evidence of ongoing inflammatory signaling months after acute infection (Phetsouphanh et al., 2022; Su et al., 2022). Mast-cell activation has also been proposed as a contributor to symptom clusters involving flushing, itching, airway reactivity, and sensory hypersensitivity (Afrin et al., 2020; Weinstock et al., 2021). These immune processes directly influence vascular permeability and neural excitability. Histamine and inflammatory mediators can increase sensory sensitivity, alter blood flow dynamics, and lower the threshold for neural activation, creating conditions in which internal signals are more likely to be perceived as sound.
Neuroinflammation provides a third layer of interaction. Both tinnitus and Long COVID have been associated with altered central nervous system processing, including increased neural gain and disrupted sensory filtering (Shore et al., 2016; Boldrini et al., 2021). Microglial activation and cytokine signaling may further amplify sensory input, contributing to persistent perception of auditory stimuli in the absence of external sound. When these domains interact, they form a feedback system rather than independent pathways. Immune activation influences vascular and neural sensitivity. Autonomic instability alters perfusion and pressure. Central sensitization amplifies signal perception.
This integrated model explains several features that are otherwise difficult to reconcile within traditional frameworks. Tinnitus may fluctuate rather than remain constant, intensify with stress or physiologic instability, and co-occur with symptoms such as internal vibrations, sensory overload, and sleep disruption. These patterns are consistent with a system in which small changes in underlying state produce disproportionate changes in sensory output.
3. HEADPRESSURE-Mod™: Modeling Pressure-Adjacent Neuroinflammation
One of the persistent challenges in Long COVID is the discrepancy between symptom severity and objective findings. Patients frequently report head pressure, tinnitus, visual strain, and neurologic discomfort despite normal imaging and standard neurological evaluations. This gap suggests that conventional diagnostic tools may not fully capture relevant aspects of neuroinflammatory or neurovascular dysfunction.
HEADPRESSURE-Mod™ is designed to address this limitation by modeling pressure-associated neuroinflammatory states using patient-reported signals that are often overlooked or fragmented in clinical practice. These include mastoid sensitivity, brainstem pressure sensations, ocular or visual pressure, tinnitus, and response to interventions.
The model is expressed as:
HeadPressure Index = (Mastoid Sensitivity + Brainstem Pressure + Visual Pressure Signals) ÷ Relief Response
This framework aligns with emerging research on glymphatic dysfunction, neuroinflammation, and vascular dysregulation in post-viral and neuroimmune conditions (Iliff et al., 2012; Nath, 2020; Zlokovic, 2011). These processes may alter intracranial fluid dynamics and pressure regulation without producing clear structural abnormalities on imaging. Within this model, tinnitus is interpreted as a pressure-adjacent signal, reflecting instability in neurovascular regulation rather than isolated auditory pathology. This perspective helps explain why tinnitus often coexists with sensations of fullness, pressure, or internal movement, and why it may respond to interventions that influence sleep, inflammation, or autonomic balance rather than purely auditory treatments.
4. Mapping Tinnitus Across CYNAERA Long COVID Phenotypes
Tinnitus becomes more interpretable when mapped across CYNAERA’s 25+ Long COVID phenotyping framework. Rather than representing a standalone condition, it appears as a cross-domain signal that emerges within multiple interacting phenotype clusters. Patients whose tinnitus fluctuates with stress, exertion, or positional change often align with autonomic and circulatory instability, which has been widely described in Long COVID cohorts as involving dysregulated heart rate, blood pressure variability, and impaired vascular tone (Barizien et al., 2021; Dani et al., 2021). These mechanisms directly affect cerebral and cochlear perfusion, both of which are known to influence auditory signaling (Nomiya et al., 2013).
In contrast, patients who experience tinnitus alongside itching, flushing, food reactivity, or environmental sensitivity may reflect immune activation and mast-cell involvement. Mast-cell activation and histamine signaling have been proposed as contributors to Long COVID symptom clusters, particularly those involving sensory reactivity and multi-system inflammation (Afrin et al., 2020; Weinstock et al., 2021). Histamine’s role in modulating both vascular permeability and neural excitability provides a plausible pathway linking immune dysregulation to auditory perception.
When tinnitus co-occurs with brain fog, sensory overload, or cognitive disruption, neuroinflammatory processes are likely contributing. Neuroinflammation and altered central processing have been documented in both tinnitus and Long COVID, with evidence suggesting increased neural gain and impaired sensory filtering (Shore et al., 2016; Boldrini et al., 2021). These mechanisms may amplify internally generated signals, making them perceptible as sound.
In patients reporting internal vibrations, tremors, and sleep disruption, tinnitus may be part of a broader neuro-excitability state. Such symptoms have been described in Long COVID cohorts and are consistent with dysregulated autonomic and central nervous system activity (Davis et al., 2023; Yong, 2021).
Environmental overlays further shape symptom expression. Exposure to mold, airborne particulates, volatile organic compounds, or heat has been associated with worsening symptoms in sensitive individuals, likely through immune and autonomic pathways (EPA, 2023; Mendell et al., 2011). These exposures can amplify tinnitus in susceptible patients, reinforcing the role of external load in destabilizing system state.
Chart: Tinnitus as a Cross-Domain Signal
Domain | Dominant Driver | Tinnitus Expression Pattern |
Autonomic | Blood pressure, stress, exertion | Fluctuates with stress, standing, dehydration |
Immune | Histamine, cytokines, MCAS | Co-occurs with itching, flushing, reactivity |
Neuroinflammatory | CNS sensitization | Linked to brain fog, sensory overload |
Sleep/Excitability | Insomnia, neural overactivation | Worsens with poor sleep, improves with stabilization |
Environmental | Mold, chemicals, heat | Triggered or amplified by exposure |
Structural-Auditory | Hearing loss, injury | Persistent, less fluctuation |
When interpreted through this framework, tinnitus is no longer an isolated symptom. It is a shared output across multiple domains, with different dominant drivers in different patients. This reframing allows tinnitus to move from a symptom to suppress toward a signal to interpret, providing insight into underlying system behavior and enabling more precise, phenotype-aligned intervention strategies.
5. HEADPRESSURE-Mod™: Quantifying Neuroinflammatory Pressure States
To capture these patterns, CYNAERA introduces HEADPRESSURE-Mod™, a system designed to model brainstem and intracranial pressure-type symptoms in patients without clear structural abnormalities on imaging. This framework integrates mastoid sensitivity, brainstem pressure sensations, ocular or visual pressure, tinnitus intensity, and response to relief interventions into a single interpretive index. The model is expressed as:
HeadPressure Index = (Mastoid Sensitivity + Brainstem Pressure + Visual Pressure Signals) ÷ Relief Response
The rationale for this model is supported by emerging research on neurovascular coupling, glymphatic function, and neuroinflammation. The glymphatic system, which facilitates clearance of metabolic waste from the brain, is influenced by sleep, vascular dynamics, and inflammatory signaling (Iliff et al., 2012). Disruption of this system has been proposed as a contributor to persistent neurologic symptoms following infection (Nath, 2020).
Similarly, endothelial dysfunction and altered cerebral blood flow have been documented in post-COVID conditions and may influence intracranial pressure dynamics without producing overt structural abnormalities (Zlokovic, 2011; Lee et al., 2022). These mechanisms provide a plausible explanation for symptoms such as head pressure, visual strain, and tinnitus in the absence of clear imaging findings. Within this framework, tinnitus is interpreted as a pressure-adjacent signal, reflecting instability in neurovascular regulation rather than isolated auditory pathology. This perspective helps explain why tinnitus often coexists with sensations of fullness, cranial pressure, or internal movement, and why it may respond to interventions that influence sleep, inflammation, or autonomic balance.
6. Therapeutic Crosswalk: From Generic Tinnitus Care to Phenotype-Aligned Combination Logic
When tinnitus therapies are evaluated in isolation, their effects appear inconsistent. However, this inconsistency becomes more coherent when each intervention is mapped to the system domain it influences. Tinnitus does not arise from a single pathway in Long COVID. It reflects interactions between autonomic regulation, immune activity, neuroinflammation, sensory amplification, sleep architecture, and environmental load. Most existing therapies act on one of these domains, but are rarely applied in a coordinated or phenotype-specific manner.
This creates a mismatch between treatment and mechanism. What appears to be therapeutic failure is often a problem of misalignment rather than inefficacy. For example, sound therapy reduces auditory salience by altering central processing, a mechanism supported by studies demonstrating changes in neural activity with acoustic stimulation (Noreña and Farley, 2013). Sleep-targeted interventions may reduce tinnitus indirectly by improving sleep architecture and reducing neural excitability (Mazurek et al., 2015). Vagus nerve stimulation and breathing-based interventions influence autonomic tone, which is increasingly recognized as a key contributor to symptom variability in both tinnitus and Long COVID (Ylikoski et al., 2020).
Antihistamines and immune-modulating approaches, while not traditionally emphasized in tinnitus care, align with evidence of immune involvement in both conditions (Phetsouphanh et al., 2022; Afrin et al., 2020). Similarly, environmental control strategies address external drivers of immune and autonomic instability, which have been linked to symptom exacerbation in susceptible populations (Mendell et al., 2011).
Chart: Tinnitus Therapeutics Mapped to System Domains
Therapeutic Approach | Primary Domain Targeted | Mechanistic Role |
Sound therapy, white noise, tinnitus apps | Sensory / CNS processing | Reduces auditory gain and perceptual salience |
Melatonin and sleep interventions | Sleep / neuro-excitability | Improves sleep architecture and lowers next-day amplification |
Vagus activation, breathing regulation | Autonomic | Shifts toward parasympathetic tone, stabilizes vascular signaling |
Manual therapy (cervical, TMJ, mastoid) | Somatosensory / pressure | Modulates mechanical and sensory input affecting auditory pathways |
Hearing aids / auditory devices | Structural-auditory | Restores input, reduces compensatory neural activity |
H1 / H2 antihistamines | Immune / histamine | Reduces histamine-driven inflammation and reactivity |
Cyproheptadine | Immune + CNS + sensory | Dampens histamine signaling, serotonergic amplification, and neural excitability |
Autonomic support (hydration, salt, pacing) | Circulatory / autonomic | Stabilizes perfusion and orthostatic regulation |
Environmental load reduction | External / immune-autonomic | Reduces trigger-driven system destabilization |
This crosswalk demonstrates that tinnitus therapies are not competing approaches, but partial interventions targeting different domains of the same system. The logical next step is not to choose between them, but to combine them based on phenotype.
7. Phenotype-Aligned Combination Strategies for Tinnitus in Long COVID
If tinnitus reflects system instability, then treatment must address the dominant drivers of that instability. This requires combination strategies that are both targeted and sequenced. The importance of sequencing is supported by broader work in chronic illness and neuroimmune conditions, where intervention timing and system readiness influence treatment outcomes (Komaroff and Lipkin, 2021). In Long COVID, where multiple systems are dysregulated simultaneously, addressing downstream symptoms without stabilizing upstream drivers may produce limited or temporary benefit.
Chart: Phenotype-Based Combination Logic and Likely Intervention Order
Phenotype | Dominant Drivers | Combination Strategy (Most Likely Order) |
Immune-Volatility / MCAS-Overlap | Histamine, inflammation, environmental reactivity | H1/H2 blockade → environmental trigger reduction → sleep stabilization → CNS dampening |
Autonomic-Neurovascular | Blood pressure instability, perfusion shifts, stress reactivity | Hydration and salt support → pacing → vagal activation → sleep stabilization |
Sensory-Amplification / Neuro-Excitability | CNS overactivation, internal vibrations, insomnia | Sleep stabilization → CNS dampening → sound modulation → autonomic regulation |
HEADPRESSURE / Neuroinflammatory Pressure | Brainstem pressure, mastoid sensitivity, glymphatic disruption | Sleep and positional optimization → anti-inflammatory stabilization → autonomic regulation → environmental reduction |
Environmental-Trigger Dominant | Mold, chemicals, heat | Exposure reduction → immune stabilization → autonomic support → sleep recovery |
Structural-Auditory | Hearing loss, cochlear dysfunction | Audiology → hearing support → sound therapy → adjunct stabilization if overlap present |
This framework reflects a fundamental shift in approach. Treatment is no longer defined by the question, “Which therapy treats tinnitus?” Instead, it becomes, “Which systems are unstable, and in what order should they be stabilized?” Within this model, tinnitus improvement is not the primary intervention target. It is the result of successful system stabilization across interacting domains.
8. Cyproheptadine Within the Combination Framework
Within phenotype-aligned strategies, certain pharmacologic signals that are not traditionally emphasized in tinnitus care become more relevant. Cyproheptadine is one such example. Cyproheptadine is a first-generation antihistamine with additional antiserotonergic properties and central nervous system effects. While its clinical use has declined in favor of less sedating second-generation antihistamines, its broader receptor profile allows it to influence multiple domains simultaneously, including histamine signaling, serotonergic modulation, and neural excitability (Simons and Simons, 2011; Stahl, 2013). In the context of Long COVID, where persistent immune activation, mast-cell involvement, and central sensitization have all been proposed as contributing mechanisms, this multi-domain activity becomes clinically relevant (Phetsouphanh et al., 2022; Afrin et al., 2020; Boldrini et al., 2021). Histamine is known to modulate both vascular permeability and neural signaling, while serotonergic pathways play a role in sensory processing, sleep regulation, and central gain (Haas et al., 2008; Shore et al., 2016).
In patients with overlapping immune volatility, sensory amplification, autonomic instability, and sleep disruption, cyproheptadine may therefore function as a system-level stabilizer. By dampening histamine-mediated reactivity and modulating central excitability, it may reduce the conditions under which sensory signals are amplified. This effect is not specific to tinnitus. Reductions in internal vibrations, tremor-like activity, sleep disruption, and emotional overactivation suggest a broader impact on system state rather than a targeted auditory mechanism. Within this framework, tinnitus decreases not because the ear is treated directly, but because the threshold for generating the signal is no longer met. Importantly, this effect is not universal. In patients whose tinnitus is primarily structural or unrelated to immune-autonomic instability, cyproheptadine may produce sedation without meaningful improvement. This variability reinforces a central principle of the paper: treatment response depends on phenotype alignment rather than symptom targeting alone.
Example: Mapping a Long COVID Tinnitus Patient Toward Symptom Remission
A Long COVID patient presents with persistent tinnitus that worsens at night, increases after stressful days, spikes following caffeine intake, and intensifies with mold or fragrance exposure. The patient also reports internal vibrations, itchy feet, poor sleep, orthostatic dizziness, and intermittent flushing following high-histamine foods. Within a conventional tinnitus model, this patient might be managed with sound masking, referral to ENT, and reassurance. While these steps remain appropriate for excluding structural causes such as hearing loss or otologic pathology, they do not account for the broader symptom pattern. Instead, the presentation is consistent with a cross-domain instability profile.
Chart: Phenotype Mapping
Signal | Interpretation | CYNAERA Phenotype Slot |
Tinnitus worsens with stress and caffeine | Sympathetic activation, vascular sensitivity | Autonomic-Neurovascular |
Tinnitus worsens with mold/fragrance | Environmental and immune reactivity | Immune-Volatility / Environmental Overlay |
Itchy feet, flushing, food reactivity | Histamine-driven response pattern | MCAS-Overlap |
Internal vibrations | Central excitability and sensory amplification | Sensory-Amplification |
Poor sleep worsens tinnitus | Impaired nocturnal regulation | Sleep / Neuro-Excitability |
Orthostatic dizziness | Circulatory instability | Autonomic & Circulatory Axis |
This patient is not simply experiencing tinnitus. They represent an immune-autonomic sensory-amplification subtype, in which tinnitus is one of several outputs of system instability.
Remission Pathway for the Symptom
The therapeutic objective is not to suppress tinnitus directly, but to reduce the system conditions required to generate it.
Chart: Remission Pathway
Phase | Intervention Logic | Expected Tinnitus Response |
1. Reduce environmental load | Limit mold, fragrance, heat, VOC exposure | Reduced trigger-driven spikes |
2. Stabilize immune/histamine activity | H1/H2 blockade, lower histamine load | Lower baseline reactivity |
3. Stabilize autonomic regulation | Hydration, salt, pacing, vagal support | Reduced stress-linked amplification |
4. Restore nighttime regulation | Sleep stabilization, CNS dampening | Reduced nighttime intensity and internal vibrations |
5. Reinforce sensory stability | Sound modulation, reduced sensory load | Tinnitus becomes less intrusive |
What Remission Looks Like in This Model
Remission in this framework does not require complete elimination of tinnitus. Instead, it reflects a shift in system state. Initially, trigger-induced spikes become less frequent as environmental and immune inputs are reduced. Baseline intensity decreases as inflammatory and autonomic instability is stabilized. Over time, the patient observes that stress no longer reliably amplifies symptoms, sleep improves, and internal vibrations diminish. Tinnitus may persist at a low level but loses its volatility and functional impact. This progression is consistent with observations in Long COVID, where symptom improvement often occurs through gradual stabilization rather than abrupt resolution (Davis et al., 2023; Lugtu et al., 2026) .
In CYNAERA terms:
Tinnitus remission occurs when immune volatility, autonomic instability, environmental load, and sensory amplification fall below the threshold required to sustain auditory signal amplification.
9. Clinical, Trial Design, and Research Implications
A state-dependent, phenotype-driven model of tinnitus has implications that extend beyond individual patient care. In clinical settings, this model supports a shift from symptom-based treatment toward pattern recognition and system stabilization. Rather than asking whether a given therapy treats tinnitus, clinicians can evaluate which system is most unstable and prioritize interventions accordingly. This approach aligns with the broader recognition that Long COVID is a multi-system condition requiring integrated management strategies (National Academies of Sciences, Engineering, and Medicine, 2024).
In research, phenotype stratification becomes critical. Trials that enroll heterogeneous tinnitus populations without accounting for underlying mechanisms are likely to produce inconclusive or diluted results. By contrast, studies that stratify participants based on autonomic, immune, neuroinflammatory, or structural drivers may be better positioned to detect meaningful treatment effects. This approach is consistent with emerging recommendations in Long COVID research, which emphasize sub-phenotyping and trajectory-based modeling to improve study design and therapeutic targeting (Geng et al., 2024; National Academies of Sciences, Engineering, and Medicine, 2024). Large-scale analyses further demonstrate that symptoms persist while shifting across domains, reinforcing the need for models that account for dynamic system behavior rather than static endpoints (Lugtu et al., 2026) .
Frameworks such as HEADPRESSURE-Mod™ also highlight the importance of capturing clinically meaningful signals that fall outside conventional diagnostic categories. Symptoms such as tinnitus, mastoid sensitivity, and head pressure may reflect underlying neurovascular and inflammatory processes that are not visible through standard imaging but remain critical to patient experience and disease progression.
10. Conclusion
Tinnitus in Long COVID is not best understood as a fixed auditory disorder. It is a dynamic, state-dependent signal emerging from interactions between autonomic instability, immune-mediated inflammation, vascular dysregulation, and central nervous system sensitization. This perspective explains the variability, fluctuation, and inconsistent treatment response observed in both general and Long COVID populations. It also provides a pathway forward.
By mapping tinnitus across phenotype domains and aligning interventions with underlying system drivers, it becomes possible to move beyond trial-and-error care. Long COVID offers a unique opportunity to advance this shift. Because symptom clusters, triggers, and trajectories are more visible, tinnitus can be studied within a structured, multi-system framework. This allows for more precise classification, more targeted therapeutic strategies, and a more realistic understanding of treatment response. Tinnitus may not be untreatable. It may have been misclassified.
Frequently Asked Questions
Is tinnitus a common symptom of Long COVID?
Yes. Tinnitus has been reported in a significant subset of Long COVID patients, often alongside symptoms such as brain fog, sleep disruption, autonomic dysfunction, and sensory sensitivity (Beukes et al., 2021; Davis et al., 2023). However, its presentation is highly variable, suggesting it reflects underlying system instability rather than a single mechanism.
Why does tinnitus in Long COVID seem to change over time?
Unlike structural ear damage, tinnitus in Long COVID often fluctuates because it is influenced by dynamic factors such as autonomic tone, immune activity, sleep quality, and environmental exposure. Large-scale data show that Long COVID symptoms persist while shifting across domains, supporting a state-dependent model (Lugtu et al., 2026).
Is tinnitus in Long COVID caused by ear damage?
In some cases, structural auditory damage may contribute. However, many patients experience tinnitus without measurable hearing loss or identifiable ear pathology. In these cases, tinnitus is more likely driven by interactions between neuroinflammation, vascular regulation, and central sensory processing (Shore et al., 2016; Boldrini et al., 2021).
Why do standard tinnitus treatments often not work?
Most treatments target a single pathway, such as auditory perception or stress response. However, tinnitus in Long COVID often arises from multiple interacting systems. When the underlying drivers are not addressed, treatment effects may be limited or inconsistent.
Can tinnitus improve without directly treating the ear?
Yes. In many cases, tinnitus improves when underlying system instability is reduced. Stabilizing immune activity, autonomic function, sleep, and environmental triggers can lower the conditions required to generate the tinnitus signal, even without direct auditory intervention.
What is a phenotype-based approach to tinnitus?
A phenotype-based approach classifies patients based on dominant system drivers, such as autonomic instability, immune activation, neuroinflammation, or sensory amplification. This allows treatments to be aligned with underlying mechanisms rather than applied uniformly.
Why might antihistamines or medications like cyproheptadine help some patients?
In patients with histamine-driven or sensory-amplified symptom patterns, antihistamines may reduce immune reactivity and neural excitability. Cyproheptadine, with additional central effects, may further dampen sensory amplification and improve sleep. However, these effects are phenotype-dependent and not universal.
What does remission of tinnitus look like in Long COVID?
Remission does not always mean complete disappearance. More often, it involves reduced intensity, fewer trigger-related spikes, improved sleep, and decreased sensory dominance. In a state-dependent model, remission occurs when system instability falls below the threshold required to sustain the tinnitus signal.
CYNAERA Framework Papers and Core Research Libraries
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library, ME/CFS Library, Lyme Library, Autoimmune Library and CRISPR Remission Library are also in depth resources.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.
Licensing and Integration
CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.
About the Author
Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.
Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey, Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.
She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.
Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.
References
Afrin, L.B., Weinstock, L.B. and Molderings, G.J. (2020) ‘Covid-19 hyperinflammation and post-COVID-19 illness may be rooted in mast cell activation syndrome’, International Journal of Infectious Diseases, 100, pp. 327–332.
Baguley, D., McFerran, D. and Hall, D. (2013) ‘Tinnitus’, The Lancet, 382(9904), pp. 1600–1607.
Barizien, N., Le Guen, M., Russel, S., Touche, P., Huang, F. and Vallée, A. (2021) ‘Clinical characterization of dysautonomia in long COVID-19 patients’, Scientific Reports, 11, 14042.
Beukes, E.W., Baguley, D.M., Jacquemin, L., Lourenco, M.P.C.G., Allen, P.M., Onozuka, J., Stockdale, D. and Andersson, G. (2021) ‘Changes in tinnitus experiences during the COVID-19 pandemic’, Frontiers in Public Health, 9, 592878.
Bhatt, J.M., Lin, H.W. and Bhattacharyya, N. (2016) ‘Prevalence, severity, exposures, and treatment patterns of tinnitus in the United States’, JAMA Otolaryngology–Head & Neck Surgery, 142(10), pp. 959–965.
Boldrini, M., Canoll, P.D. and Klein, R.S. (2021) ‘How COVID-19 affects the brain’, JAMA Psychiatry, 78(6), pp. 682–683.
Cederroth, C.R., Gallus, S., Hall, D.A., Kleinjung, T., Langguth, B., Maruotti, A., Meyer, M., Norena, A., Probst, T., Pryss, R., et al. (2019) ‘Towards an understanding of tinnitus heterogeneity’, Frontiers in Aging Neuroscience, 11, 53.
Dani, M., Dirksen, A., Taraborrelli, P., Torocastro, M., Panagopoulos, D., Sutton, R. and Lim, P.B. (2021) ‘Autonomic dysfunction in “long COVID”: Rationale, physiology and management strategies’, Clinical Medicine, 21(1), pp. e63–e67.
Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023) ‘Long COVID: Major findings, mechanisms and recommendations’, Nature Reviews Microbiology, 21, pp. 133–146.
EPA (2023) Indoor Air Quality and Health Effects. U.S. Environmental Protection Agency.
Geng, L.N., et al. (2024) ‘Phenotyping post-acute sequelae of SARS-CoV-2 infection’, Nature Medicine, 30, pp. 1–10.
Haas, H.L., Sergeeva, O.A. and Selbach, O. (2008) ‘Histamine in the nervous system’, Physiological Reviews, 88(3), pp. 1183–1241.
Iliff, J.J., Wang, M., Liao, Y., Plogg, B.A., Peng, W., Gundersen, G.A., Benveniste, H., Vates, G.E., Deane, R., Goldman, S.A., et al. (2012) ‘A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes’, Science Translational Medicine, 4(147).
Kleinjung, T., et al. (2024) ‘Tinnitus: Causes, mechanisms, and treatments’, The Lancet Neurology, 23(1), pp. 1–15.
Komaroff, A.L. and Lipkin, W.I. (2021) ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome’, Trends in Molecular Medicine, 27(9), pp. 895–906.
Lugtu, K., et al. (2026) ‘Prevalence and evolution of long COVID symptoms: A meta-analysis’, Journal of Infection, 92(1), pp. 101–115.
Mazurek, B., Haupt, H., Olze, H. and Szczepek, A.J. (2015) ‘Stress and tinnitus—from bedside to bench and back’, Frontiers in Systems Neuroscience, 9, 47.
Mendell, M.J., Mirer, A.G., Cheung, K., Tong, M. and Douwes, J. (2011) ‘Respiratory and allergic health effects of dampness, mold, and dampness-related agents’, Environmental Health Perspectives, 119(6), pp. 748–756.
Nalbandian, A., Sehgal, K., Gupta, A., Madhavan, M.V., McGroder, C., Stevens, J.S., Cook, J.R., Nordvig, A.S., Shalev, D., Sehrawat, T.S., et al. (2021) ‘Post-acute COVID-19 syndrome’, Nature Medicine, 27, pp. 601–615.
Nath, A. (2020) ‘Long-haul COVID’, Neurology, 95(13), pp. 559–560.
Nomiya, S., et al. (2013) ‘The role of microcirculation in tinnitus’, Acta Oto-Laryngologica, 133(11), pp. 1115–1121.
Noreña, A.J. and Farley, B.J. (2013) ‘Tinnitus-related neural activity: Theories of generation, propagation, and centralization’, Hearing Research, 295, pp. 161–171.
Phetsouphanh, C., Darley, D.R., Wilson, D.B., Howe, A., Munier, C.M.L., Patel, S.K., Juno, J.A., Burrell, L.M., Kent, S.J., Dore, G.J., et al. (2022) ‘Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection’, Nature Immunology, 23, pp. 210–216.
Shore, S.E., Roberts, L.E. and Langguth, B. (2016) ‘Maladaptive plasticity in tinnitus—Triggers, mechanisms and treatment’, Nature Reviews Neurology, 12, pp. 150–160.
Simons, F.E.R. and Simons, K.J. (2011) ‘Histamine and H1-antihistamines: Celebrating a century of progress’, Journal of Allergy and Clinical Immunology, 128(6), pp. 1139–1150.
Stahl, S.M. (2013) Stahl’s Essential Psychopharmacology. Cambridge University Press.
Turner, G.M., et al. (2023) ‘Mechanisms of long COVID: A review’, Nature Reviews Immunology, 23, pp. 1–15.
Weinstock, L.B., Brook, J.B., Walters, A.S., Goris, A. and Afrin, L.B. (2021) ‘Mast cell activation symptoms are prevalent in Long-COVID’, International Journal of Infectious Diseases, 112, pp. 217–226.
Yellamsetty, A., et al. (2025) ‘Tinnitus following COVID-19 vaccination: Characteristics and possible mechanisms’, Frontiers in Neurology, 16.
Yong, S.J. (2021) ‘Persistent brainstem dysfunction in long-COVID: A hypothesis’, ACS Chemical Neuroscience, 12(4), pp. 573–580.
Zlokovic, B.V. (2011) ‘Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders’, Nature Reviews Neuroscience, 12, pp. 723–738.
How to Cite this Paper
Adinig, C. (2026) Tinnitus in Long COVID: A State-Dependent Neurovascular Model Integrating Autonomic Instability, Immune Volatility, and Phenotype-Aligned Combination Therapy. CYNAERA. Available at: https://www.cynaera.com/tinnitus-lc
Comments